Stocks and Finance

Gilead Sciences

Gilead Sciences 2/28/2012

13:30 : GILD, SPLS & ODP - Bullish options build on biotech company Gilead Sciences - Today’s tickers: GILD, SPLS & ODP GILD – Gilead Sciences, Inc. – Bullishactivity in the biotechnology company’s options jumped and shares in GileadSciences moved up more than 2.0% to $46.18 the same day the drug makerpresented at ...
Source : fxstreet-com

Gilead Sciences 2/14/2012

10:32 : Gilead Sciences ([[GILD]] -0.9%) anti-retroviral drug Truvada has been ... - Gilead Sciences (GILD -0.9%) anti-retroviral drug Truvada has been granted a priority-review schedule by the FDA, advancing what could become the first treatment labeled for HIV prevention. Post your comment!
Source : seekingalpha-com

Gilead Sciences 12/20/2011

17:44 : Gilead Sciences (GILD) says the European Medicines Agency has validated ... - Gilead Sciences (GILD) says the European Medicines Agency has validated the Marketing Authorization Application for its quad single-tablet regimen used in the treatment of HIV-1 infection in adults. When finalized, the marketing ...
Source : seekingalpha-com

Gilead Sciences 11/21/2011

09:25 : Gilead Sciences to raise $6B in Debt, Suspend Share Buybacks Over $11B ... - Gilead Sciences, Inc. (NASDAQ:GILD) would raise $6 billion in debt and suspend share buybacks as part its $11 billion acquisition of Pharmasset, Inc. (NASDAQ:VRUS), according to a Wall Street analyst.
Source : ibtimes-com
08:22 : Gilead Sciences to buy Pharmasset for $11 billion - FOSTER CITY, Calif. (AP) -- Gilead Sciences Inc. said Monday that it has agreed to pay about $11 billion for drug developer Pharmasset Inc. in a huge bet on its experimental hepatitis C treatments. The offer is ...
Source : usnews-com
07:57 : Pharmasset agrees to $11B bid by Gilead Sciences - TEL AVIV (MarketWatch) - Pharmasset Inc., the Princeton, N.J., developer of oral therapies to treat hepatitis C, agreed to be acquired for $137 cash a share, or $11 billion, by Gilead Sciences Inc. Gilead is the ...
Source : marketwatch-com

Gilead Sciences 9/19/2011

17:09 : Gilead Sciences (GILD) says the HIV Phase 3 clinical trial of its potentia - Gilead Sciences (GILD) says the HIV Phase 3 clinical trial of its potential blockbuster “Quad” regimen used for the treatment of HIV-1 met its primary endpoint. Post your comment!
Source : seekingalpha-com

Gilead Sciences 8/10/2011

16:31 : Gilead Sciences (GILD) and Johnson & Johnson (JNJ) win FDA approval of ... - Gilead Sciences (GILD) and Johnson Johnson (JNJ) win FDA approval of a once-daily HIV treatment that combines multiple medicines into one tablet. The combination product, called Complera, is expected to generate $567M in revenue ...
Source : seekingalpha-com

Gilead Sciences 6/28/2011

15:46 : Shares of Gilead Sciences ([[GILD]] +1.9%) and Johnson & Johnson ([[JNJ]] - Shares of Gilead Sciences (GILD +1.9%) and Johnson Johnson (JNJ +1%) gain after the drugmakers announce they are teaming up to produce a fixed dose combination HIV drug. Gilead will receive a flat royalty as a percentage of net ...
Source : seekingalpha-com

Gilead Sciences 5/27/2011

07:55 : Analyst Research on Gilead Sciences Inc. and Human Genome Sciences Inc. ... - JOHANNESBURG, SOUTH AFRICA--(Marketwire - May 27, 2011) - www.stockcall.com/ offers investors comprehensive research on the Biotechnology industry and has completed analytical research on Gilead Sciences Inc. (NASDAQ: GILD) and ...
Source : marketwire-com
actualidad Gilead Sciences -


Biotechnology

Pharmaceuticals

Medical Supplies

Medical Equipment

Health Care Providers

Copyright © 2009 Finaperf.com - Exchange rate - Investir - Stock Exchange - Börse - Finanças - Bolsa - Tous droits réservés
Site édité par Yanga.net - Contacts